Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014;18(18):2596-8.

NT-proBNP plays an important role in the effect of ibuprofen on preterm infants with patent ductus arteriosus

Y-J Ding  1 , B Han, B Yang, M Zhu
Affiliations
  • PMID: 25317790
Free article
Randomized Controlled Trial

NT-proBNP plays an important role in the effect of ibuprofen on preterm infants with patent ductus arteriosus

Y-J Ding et al. Eur Rev Med Pharmacol Sci. 2014.
Free article

Abstract

Objective: The aim of this study was to clarify the role of N-terminal pro-brain natriuretic peptide, (NT-proBNP) in ibuprofen on preterm infants with patent ductus arteriosus (PDA).

Patients and methods: Preterm infants with PDA were enrolled in the present study. Patients were randomized into two groups: ibuprofen group received oral ibuprofen 10 mg/kg, followed by 5 mg/kg after 24 and 48 h, and the placebo group received the same volume of 5% glucose. PDA and NT-proBNP were detected during 24 hours, 3 and 7 days of age.

Results: The results indicated that babies who received oral ibuprofen had higher PDA closure at 7 days after treatment (p < 0.05). Significantly decrease of NT-proBNP was found in ibuprofen group than the placebo group at 3 and 7 days (all p < 0.05).

Conclusions: Collectively, the favorable effects of ibuprofen on PDA in premature infants maybe mediated in part by the reduction of NT-proBNP level.

PubMed Disclaimer

Publication types